Research Article

Evaluation of infective endocarditis agents

Volume: 42 Number: 2 June 30, 2025
TR EN

Evaluation of infective endocarditis agents

Abstract

Endocarditis is an inflammation or microbial infection of the heart valves and the endocardium of the heart. Bacteria that enter the blood due to various reasons can multiply in the endocardial layer of the heart and cause infection. In addition, these infections can be carried to different parts of the body through the bloodstream. This study aims to evaluate the distribution of microorganisms grown in blood cultures taken from patients diagnosed with endocarditis. The distribution of microorganisms grown in blood culture samples sent from patients diagnosed with endocarditis to our Ondokuz Mayıs University Medical Microbiology Laboratory between 2018-2021 was retrospectively examined. The distributions of the most frequently isolated bacteria from 63 strains obtained from blood samples are as follows; 61.90% Staphylococcus spp., 11.11% Streptococcus spp., 9.52% Enterococcus spp., 3.17% Escherichia coli, 1.58% Enterobacter cloacae, 6.34% Klebsiella pneumoniae, 1.58% Acinetobacter baumannii, 1.58% Stenotrophonomonas maltophilia, 1.58% Corynebacterium stratum, 1 1.58% Micrococcus spp. Oxacillin resistance was detected as 44.44% in S. aureus isolates. Carbapenem resistance was not detected in Enterobactarales bacteria. Vancomycin resistance was not detected in enterococcus isolates. Despite significant developments in the diagnosis and treatment of infective endocarditis, there has been no decrease in its incidence and mortality. Similar to many articles in the literature, it has been determined that the most frequently isolated pathogen is S. aureus. Knowing the distribution of infective endocarditis agents is important in guiding clinicians in both prophylactic and empirical treatment selection.

Keywords

Ethical Statement

Decision No: OMU KAEK 2024/462

References

  1. Pericàs JM, Llopis J, Athan E, Hernández-Meneses M, Hannan MM, Murdoch DR, Kanafani Z, Freiberger T, Strahilevitz J, Fernández-Hidalgo N, Lamas C, Durante-Mangoni E, Tattevin P, Nacinovich F, Chu VH, Miró JM. International Collaboration on Endocarditis (ICE) Investigators. Prospective Cohort Study of Infective Endocarditis in People Who Inject Drugs. J Am Coll Cardiol. 2021;Feb;9:77(5):544-555.
  2. Østergaard L, Voldstedlund M, Bruun NE, Bundgaard H, Iversen K, Køber N, Christensen JJ, Rosenvinge FS, Jarløv JO, Moser C, Andersen CØ, Coia J, Marmolin ES, Søgaard KK, Lemming L, Køber L, Fosbøl EL. Temporal Changes, Patient Characteristics, and Mortality, According to Microbiological Cause of Infective Endocarditis: A Nationwide Study. J Am Heart Assoc. 2022;Aug;16:11(16):e025801.
  3. Fowler VG Jr, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, Corey GR, Spelman D, Bradley SF, Barsic B, Pappas PA, Anstrom KJ, Wray D, Fortes CQ, Anguera I, Athan E, Jones P, van der Meer JT, Elliott TS, Levine DP, Bayer AS. ICE Investigators. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA. 2005;Jun 22;293(24):3012-21.
  4. Selton-Suty C, Célard M, Le Moing V, Doco-Lecompte T, Chirouze C, Iung B, Strady C, Revest M, Vandenesch F, Bouvet A, Delahaye F, Alla F, Duval X, Hoen B. AEPEI Study Group. Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clin Infect Dis. 2012;May;54(9):1230-9.
  5. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG Jr, Bayer AS, Karchmer AW, Olaison L, Pappas PA, Moreillon P, Chambers ST, Chu VH, Falcó V, Holland DJ, Jones P, Klein JL, Raymond NJ, Read KM, Tripodi MF, Utili R, Wang A, Woods CW, Cabell CH. International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) Investigators. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2009;Mar 9:169(5):463-73.
  6. Téllez A, Ambrosioni J, Llopis J, Pericàs JM, Falces C, Almela M, Garcia de la Mària C, Hernandez-Meneses M, Vidal B, Sandoval E, Quintana E, Fuster D, Tolosana JM, Marco F, Moreno A, Miro JM. Hospital Clínic Infective Endocarditis Investigators. Epidemiology, Clinical Features, and Outcome of Infective Endocarditis due to Abiotrophia Species and Granulicatella Species: Report of 76 Cases, 2000-2015. Clin Infect Dis. 2018;Jan: 6;66(1):104-111.
  7. Gould K, Ramirez-Ronda CH, Holmes RK, Sanford JP. Adherence of bacteria to heart valves in vitro. J Clin Invest. 1975;Dec:56(6):1364-70.
  8. Erbay AR, Erbay A, Canga A, Keskin G, Sen N, Atak R, Demir AD, Balbay Y, Duru E. Risk factors for in-hospital mortality in infective endocarditis: five years' experience at a tertiary care hospital in Turkey. J Heart Valve Dis. 2010;Mar:19(2):216-24.

Details

Primary Language

English

Subjects

Medical Microbiology (Other)

Journal Section

Research Article

Publication Date

June 30, 2025

Submission Date

December 21, 2024

Acceptance Date

May 5, 2025

Published in Issue

Year 2025 Volume: 42 Number: 2

APA
Tanrıverdi Çaycı, Y., Bıyık, İ., Charehjou, M., & Bırıncı, A. (2025). Evaluation of infective endocarditis agents. Deneysel Ve Klinik Tıp Dergisi, 42(2), 146-151. https://izlik.org/JA93MN77GJ
AMA
1.Tanrıverdi Çaycı Y, Bıyık İ, Charehjou M, Bırıncı A. Evaluation of infective endocarditis agents. J. Exp. Clin. Med. 2025;42(2):146-151. https://izlik.org/JA93MN77GJ
Chicago
Tanrıverdi Çaycı, Yeliz, İlknur Bıyık, Mahsa Charehjou, and Asuman Bırıncı. 2025. “Evaluation of Infective Endocarditis Agents”. Deneysel Ve Klinik Tıp Dergisi 42 (2): 146-51. https://izlik.org/JA93MN77GJ.
EndNote
Tanrıverdi Çaycı Y, Bıyık İ, Charehjou M, Bırıncı A (June 1, 2025) Evaluation of infective endocarditis agents. Deneysel ve Klinik Tıp Dergisi 42 2 146–151.
IEEE
[1]Y. Tanrıverdi Çaycı, İ. Bıyık, M. Charehjou, and A. Bırıncı, “Evaluation of infective endocarditis agents”, J. Exp. Clin. Med., vol. 42, no. 2, pp. 146–151, June 2025, [Online]. Available: https://izlik.org/JA93MN77GJ
ISNAD
Tanrıverdi Çaycı, Yeliz - Bıyık, İlknur - Charehjou, Mahsa - Bırıncı, Asuman. “Evaluation of Infective Endocarditis Agents”. Deneysel ve Klinik Tıp Dergisi 42/2 (June 1, 2025): 146-151. https://izlik.org/JA93MN77GJ.
JAMA
1.Tanrıverdi Çaycı Y, Bıyık İ, Charehjou M, Bırıncı A. Evaluation of infective endocarditis agents. J. Exp. Clin. Med. 2025;42:146–151.
MLA
Tanrıverdi Çaycı, Yeliz, et al. “Evaluation of Infective Endocarditis Agents”. Deneysel Ve Klinik Tıp Dergisi, vol. 42, no. 2, June 2025, pp. 146-51, https://izlik.org/JA93MN77GJ.
Vancouver
1.Yeliz Tanrıverdi Çaycı, İlknur Bıyık, Mahsa Charehjou, Asuman Bırıncı. Evaluation of infective endocarditis agents. J. Exp. Clin. Med. [Internet]. 2025 Jun. 1;42(2):146-51. Available from: https://izlik.org/JA93MN77GJ